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Abstract
Several recent phase 3 clinical trials of attention-deficit/hyperactivity disorder (ADHD) medications have used the Weiss 
Functional Impairment Rating Scale-Parent Report (WFIRS-P). Here, we assess WFIRS-P response in individual patients 
in two pivotal trials of lisdexamfetamine dimesylate (LDX) and guanfacine extended release (GXR). We also analysed 
pooled WFIRS-P data from seven phase 3 studies of ADHD medications to shed light on factors associated with baseline 
functional impairment. The proportion of patients with a change in WFIRS-P score that exceeded the minimal important 
difference (MID) criteria for response was greater for LDX than placebo in the Family, Learning and School, and Risky 
Activities domains, and was greater for GXR than placebo in the Social Activities, Learning and School, and Family domains. 
Responders had significantly worse baseline scores in all WFIRS-P domains (all p < 0.001) than non-responders. In the 
pooled analyses, baseline WFIRS-P scores in all domains were significantly worse in participants with oppositional defiant 
disorder (ODD) than in those without ODD. Having combined type or hyperactive-impulsive type ADHD, being enrolled 
into a study in Europe, being male and being younger also had modest negative effects on baseline WFIRS-P scores. The 
present analysis of WFIRS-P response shows that previously reported group-level improvements in WFIRS-P functional 
impairment score translated into clinically relevant improvements in many individual participants. Functional impairment 
is a diverse and subjective construct that is influenced by multiple factors. Optimal management of individuals with ADHD 
should involve monitoring improvements in functioning and quality of life, as well as symptomatic improvement.
Keywords Attention-deficit/hyperactivity disorder · Weiss Functional Impairment Rating Scale-Parent · Functional 
impairment · Response
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is associ-
ated with functional impairment in multiple domains, such 
as daily life at home and at school [1, 2]. Therefore, as well 
as addressing the symptoms of ADHD, optimal treatment 
should also address the associated functional impairments 
[2]. To support this approach, the European Medicines 
Agency recommended that the endpoints of clinical trials 
of ADHD medications should reflect both symptomatic and 
functional outcomes [3].
The Weiss Functional Impairment Rating Scale-Par-
ent Report (WFIRS-P) is a psychometrically validated 
parent-rated instrument for assessing functional impair-
ment in children with ADHD [4–8], and has been used as 
an outcome measure in multiple phase 3 clinical trials of 
 * David R. Coghill 
 david.coghill@unimelb.edu.au
1 Departments of Paediatrics and Psychiatry, Faculty 
of Medicine, Dentistry and Health Science, University 
of Melbourne, Melbourne, VIC 3010, Australia
2 Murdoch Children’s Research Institute, Parkville, VIC, 
Australia
3 Shire, a Takeda company, Zug, Switzerland
4 Shire, a Takeda company, Lexington, MA, USA
5 Child and Adolescent Psychiatry, Johannes 
Gutenberg-University Mainz, Mainz, Germany
810 European Child & Adolescent Psychiatry (2021) 30:809–821
1 3
ADHD medications in children and adolescents [9–13]. The 
WFIRS-P assesses functional impairment typical of ADHD 
across six clinically relevant domains: Family; Learning and 
School (with subdomains of Learning and Behaviour); Life 
Skills; Child’s Self-Concept; Social Activities; and Risky 
Activities. Although these domains overlap with ADHD 
symptomatic impairment, functional impairment is a dis-
tinct construct [14]. As such, the WFIRS-P taps into distinct 
features not captured by symptom-based scales such as the 
ADHD Rating Scale IV (ADHD-RS-IV) [15]. Hodgkins 
et al. estimated the minimal important difference (MID) in 
WFIRS-P score for each domain [16]. The MID is a meas-
ure of the smallest change that a respondent would perceive 
as important and can be used to analyse the proportion of 
patients who respond to treatment.
The WFIRS-P was used in two pivotal randomized, 
double-blind, placebo-controlled, efficacy and safety stud-
ies of the ADHD treatments lisdexamfetamine dimesylate 
(LDX) and guanfacine extended release (GXR) [10]. Treat-
ment with LDX was associated with statistically significant 
placebo-adjusted improvements from baseline to endpoint 
in WFIRS-P total score, and domain scores for Learning 
and School, Family, Social Activities, and Risky Activities 
(all p < 0.001). In the same study, treatment with the active 
reference arm osmotic-release oral system methylphenidate 
(OROS-MPH) showed a similar pattern of improvement 
[10]. In the GXR study, placebo-adjusted improvements 
from baseline to endpoint were statistically significant in 
the WFIRS-P Learning and School, and Family domains 
(both p < 0.01) [11]. Similar improvements were seen with 
the atomoxetine (ATX) reference arm [11].
The present analyses were conducted to enhance under-
standing of the clinical relevance of previously reported 
group-level WFIRS-P outcomes from clinical trials of 
ADHD medications. First, using the anchor-based WFIRS-
P MID calculated by Hodgkins et al. [16], we assessed indi-
vidual treatment response in two pivotal trials of LDX and 
GXR which included OROS-MPH and ATX, respectively, 
as reference arms [10, 11]. Then, using pooled WFIRS-P 
data from seven phase 3 studies of ADHD medications, 
we explore demographic and clinical factors which may 
impact functional impairment in clinical trial participants 
at baseline.
Methods
WFIRS‑P treatment response analysis
Study designs and populations
Studies SPD489-325 and SPD503-316 were chosen for 
post hoc analysis of individual response because both have 
previously published group-level effect sizes in WFIRS-P 
domain and total scores for active and reference arms [10, 
11].
SPD489-325 (Cl in ica lTr ia l s .gov  ident i f ie r : 
NCT00763971) was a 7-week, double-blind, efficacy and 
safety study of LDX in children and adolescents (aged 
6–17 years) with ADHD and an ADHD-RS-IV total score 
of at least 28, conducted in Europe (48 sites in 10 countries). 
Details of the study design, results and previous post hoc 
analyses have been published [10, 15, 17–21].
SPD503-316 (Cl in ica lTr ia l s .gov  ident i f ie r : 
NCT01244490) was a 10–13-week, double-blind, efficacy 
and safety study of GXR in children and adolescents (aged 
6–17 years) with ADHD and an ADHD-RS-IV total score of 
at least 32 and a Clinical Global Impression-Severity (CGI-
S) score of at least four, conducted in Europe (45 sites in 11 
countries) and North America. Details of the study design, 
results and previous post hoc analyses have been published 
[11, 15, 22].
Both studies were placebo-controlled and included an 
active reference arm. In SPD489-325, participants were 
randomized (1:1:1) to receive dose-optimized LDX (30, 50 
or 70 mg/day), placebo or OROS-MPH (18, 36 or 54 mg/
day). In SPD503-316, participants were randomized (1:1:1) 
to receive dose-optimized GXR (children, 1–4 mg/day; ado-
lescents, 1–7 mg/day), placebo or ATX (10–100 mg/day). 
The studies were neither designed nor powered for compari-
sons between active treatments.
Pre‑specified WFIRS‑P analyses
Summaries of the pre-specified efficacy analyses from 
SPD489-325 and SPD503-316 are provided for context. In 
both studies, efficacy analyses were carried out using the full 
analysis set (FAS), defined as all participants who received 
at least one dose of investigational product. Least-squares 
means, effect sizes, and p values were based on type III 
sum of squares from an analysis of covariance model for 
the change from baseline, including treatment group, age 
group, and country as a fixed effect, and baseline value as 
covariates [10, 11]. Except for the pre-specified key second-
ary outcomes in SPD503-316 (the Family domain, and the 
Learning and School domain), p values were not adjusted for 
multiplicity and are therefore non-inferential.
Post hoc WFIRS‑P responder analyses
WFIRS-P response in each of the six domains was defined 
as a change exceeding the published MID for that domain 
(Family, 3.76; Learning and School, 3.94; Life Skills, 
3.59; Child’s Self-Concept, 1.28; Social Activities, 2.78; 
Risky Activities, 2.60) [16]. p values were not adjusted for 
multiplicity.
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To investigate the impact of the degree of impairment at 
baseline on the magnitude of improvement during the study, 
post hoc analyses were undertaken to compare baseline 
WFIRS-P scores in responders and non-responders for each 
domain, and to assess correlation between baseline WFIRS-
P score and score change from baseline in that domain. Par-
ticipants in the FAS with data at both baseline and endpoint 
were assessed for studies SPD489-325 and SPD503-316. 
The FAS was chosen as the analysis population for consist-
ency with previously reported studies, in which it was used 
as the primary population for efficacy analyses.
Factors associated with WFIRS‑P scores at baseline 
in seven clinical trials
Study designs
To explore potential factors that might be negatively associ-
ated with WFIRS-P scores at baseline (before treatment), we 
pooled data from all LDX and GXR studies that included a 
baseline assessment using the WFIRS-P.
As well as the two studies described above (SPD489-325 
and SPD503-316), LDX studies SPD489-326 and SPD489-
317, and GXR studies SPD503-315, SPD503-314 and 
SPD503-312 were included. All were randomized, double-
blind, placebo-controlled studies, except for SPD489-317 
which was a randomized, double-blind, head-to-head study 
with ATX. Key study information, and inclusion and exclu-
sion criteria are summarized in Table 1.
Post hoc pooled baseline stratifications and correlations
The FAS from each study was pooled. Defined as all par-
ticipants who received at least one dose of investigational 
product, the FAS was chosen as the analysis population for 
consistency with previously reported studies.
Participants were stratified into subgroups based on: pres-
ence of oppositional defiant disorder (ODD, with or with-
out); presence or absence of hyperactivity (‘with hyperac-
tivity’ included predominantly hyperactive-impulsive and 
combined type ADHD, ‘without hyperactivity’ included pre-
dominantly inattentive type ADHD); continent of enrolment 
(Europe or North America); and sex (male or female). Stand-
ardized mean differences (SMD) between subgroups were 
calculated as Hedges g (SMD ≥ 0.8 was considered large; 
SMD ≥ 0.5 was considered medium; SMD ≥ 0.2 was consid-
ered small) [23]. The effect of participants’ ages was inves-
tigated using linear regression (Pearson’s r). Only p values 
below 0.001 are quoted. Subgroup categories were selected 
based on a standard set of baseline clinical and demographic 




In the SPD489-325 study, 336 participants were randomized 
and 317 were included in the FAS, of whom 80/104, 42/106 
and 74/107 in the LDX, placebo and OROS-MPH groups, 
respectively, completed the study [17]. The mean age of 
participants in the FAS was 10.9 years (standard deviation 
[SD], 2.70); 72.2% were children aged 6–12 years and 80.4% 
were boys. Overall, 15.8% of participants had predominantly 
inattentive ADHD, 3.2% had predominantly hyperactive-
impulsive ADHD and 81.0% had combined type ADHD. 
ODD affected 7.7% of the LDX group, 7.5% of the placebo 
group and 9.3% of the OROS-MPH group. Stimulant medi-
cation was previously used by 47.1%, 45.3% and 48.6% of 
the LDX, placebo and OROS-MPH groups, respectively 
(Table 2).
In the SPD503-316 study, 338 participants were ran-
domized and 337 were included in the FAS, of whom 
91/114, 92/111 and 89/112 in the GXR, placebo and ATX 
groups, respectively, completed the double-blind period 
of the study [11]. The mean age of participants in the 
FAS was 10.8 years (SD, 2.78), 71.8% were children aged 
6–12 years and 73.9% were boys. Overall, 10.7% had pre-
dominantly inattentive, 4.2% had predominantly hyperac-
tive-impulsive and 85.2% had combined type ADHD. In 
total, 12.2% had comorbid ODD and 56.3% had significant 
oppositional symptoms. Stimulant medication was previ-
ously used by 47.4%, 50.5% and 50.9% of the GXR, pla-
cebo and ATX groups, respectively (Table 2).
In both studies, the principal reason for discontinuation 
was lack of efficacy. Baseline demographics and disease 
characteristics were generally similar across treatment 
groups (Table 2).
WFIRS‑P outcomes and responder analyses in SPD489‑325
The proportion of patients with a change in WFIRS-P 
score that exceeded the MID was significantly greater for 
LDX than placebo in the Family, Learning and School, and 
Risky Activities domains (Fig. 1a). Mean improvements in 
WFIRS-P scores from baseline to endpoint were signifi-
cantly greater for LDX than for placebo in the Learning 
and School, Family, Social Activities, and Risky Activi-
ties domains, with effect sizes of 1.249, 0.730, 0.643 and 
0.640, respectively (Fig. 1a), as previously described [10].
In the OROS-MPH reference arm, the proportion of 
participants with a change in WFIRS-P score exceeding 
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the MID was significantly greater than for placebo in the 
Family, Learning and School, Social Activities, and Risky 
Activities domains (Fig. 1b). Placebo-adjusted improve-
ments in mean WFIRS-P scores were significant for 
OROS-MPH in all domains, with effect sizes in the range 
0.348–0.910 (Fig. 1b), as previously described [10].
WFIRS‑P outcomes and responder analyses in SPD503‑316
The proportion of patients with a change in WFIRS-P score 
that exceeded the MID was greater for GXR than placebo 
in the Social Activities, Learning and School, and Family 
domains (Fig. 2a). Placebo-adjusted improvements in mean 
WFIRS-P scores from baseline to endpoint were significant 
for GXR in the Social Activities, Learning and School, and 
Family domains, with effect sizes of 0.45, 0.42 and 0.38, 
respectively (Fig. 2a), as previously described [11].
In the ATX reference arm, the proportion of participants 
with a change in WFIRS-P score exceeding the MID was 
significantly greater than for placebo in the Social Activities, 
Learning and School, and Life Skills domains (Fig. 2b). Pla-
cebo-adjusted improvements in mean WFIRS-P scores were 
significant in the Learning and School domain only, with an 
effect size of 0.32 (Fig. 2b), as previously described [11].
Post hoc analysis of WFIRS‑P response
In both studies, responders had significantly worse 
baseline scores in all WFIRS-P domains (all p < 0.001) 
than non-responders (Table 3). In all domains, baseline 
WFIRS-P scores were significantly correlated with the 
change in scores from baseline (all p < 0.001), with greater 
baseline impairment associated with larger score changes.
Stratification of baseline WFIRS‑P scores by patient 
characteristic subgroups
Participants
The pooled data set from the seven studies comprised 2099 
participants, with a mean age of 11.0 years (SD, 2.92). Of 
these, 563 (26.8%) were girls, 863 (41.1%) were enrolled 
in Europe and 359 (17.1%) had comorbid ODD. In total, 
1803 (85.9%) participants were diagnosed with combined 
or predominantly hyperactive-impulsive type ADHD and 
295 (14.1%) with predominantly inattentive type ADHD 
(information was not available for one individual from 
SPD489-325).
Effect of age
Younger age correlated weakly but significantly with 
worse symptoms and functioning in the Family and 
Social Activities domains, with low values of Pearson’s r 
(– 0.1104 and – 0.1483, respectively) (Table 4). A similar 
association was seen with ADHD-RS-IV and CGI-S scores 
(– 0.2809 and – 0.2137, respectively).
Table 2  Baseline demographics and disease characteristics (FAS)
ADHD attention-deficit/hyperactivity disorder, ATX atomoxetine, FAS full analysis set, GXR guanfacine extended release, LDX lisdexamfetamine 
dimesylate, ODD oppositional defiant disorder, OROS-MPH osmotic-release oral system methylphenidate, SD standard deviation
Characteristic SPD489-325 SPD503-316
LDX (n = 104) Placebo (n = 106) OROS-MPH (n = 107) GXR (n = 114) Placebo (n = 111) ATX (n = 112)
Age, years
 Mean (SD) 10.8 (2.78) 11.0 (2.77) 10.7 (2.56) 10.9 (2.77) 11.0 (2.76) 10.5 (2.81)
 Median (range) 11.0 (6–16) 11.0 (6–17) 11.0 (6–16) 11.0 (6–17) 11.0 (6–17) 10.0 (6–16)
Sex [n (%)]
 Male 81 (77.9) 88 (83.0) 86 (80.4) 76 (66.7) 86 (77.5) 87 (77.7)
Continent of enrolment [n (%)]
Europe 104 (100) 106 (100) 107 (100) 88 (76.5) 87 (78.4) 87 (77.7)
ADHD type [n (%)]
Predominantly inattentive 22 (21.2) 15 (14.2) 13 (12.3) 15 (13.2) 11 (9.9) 10 (8.9)
Predominantly hyperactive-
impulsive
2 (1.9) 7 (6.6) 1 (0.9) 6 (5.3) 5 (4.5) 3 (2.7)
Combined 80 (76.9) 84 (79.2) 92 (86.8) 93 (81.6) 95 (85.6) 99 (88.4)
ODD diagnosis [n (%)] 8 (7.7) 8 (7.5) 10 (9.3) 17 (14.9) 14 (12.6) 10 (8.9)
Previous stimulant medica-
tion use
49 (47.1) 48 (45.3) 52 (48.6) 54 (47.4) 56 (50.5) 57 (50.9)
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Effect of sex
Baseline WFIRS-P scores in most domains were similar 
amongst male and female participants (Fig. 3a). Scores were 
slightly worse in boys than in girls in the Risky Activities 
domain and Learning and School domain, with small SMDs 
(0.34 and 0.22, respectively). CGI-S scores and ADHD-RS-
IV total scores were also slightly worse in boys than in girls, 
with small SMDs (0.18 and 0.17, respectively).
Effect of continent of enrolment
Baseline WFIRS-P scores were significantly worse in par-
ticipants enrolled in Europe than in North America in all 
domains except for the Learning and School domain, and 
the Life Skills domain (Fig. 3b). SMDs between subgroups 
were largest in the Family and Social Activities domains 
(0.55 and 0.46, respectively). Baseline CGI-S scores were 
also significantly worse in participants enrolled in Europe 
than in North America, but ADHD-RS-IV total scores were 
similar. The SMD between subgroups was 0.62 for CGI-S 
score and 0.12 for ADHD-RS-IV total score.
Effect of ODD
Baseline WFIRS-P scores in all domains were signifi-
cantly higher (worse) in participants with ODD and ADHD 
than in those without ODD (Fig.  3c). SMDs between 
the subgroups with ODD and without ODD subgroups 
were largest in the Family and Risky Activities domains 
(0.66 and 0.63, respectively). Baseline CGI-S scores and 
ADHD-RS-IV total scores were also significantly worse in 
(a)
(b)
Fig. 1  SPD489-325: post hoc responder analysis of change in 
WFIRS-P domain scores in the a LDX and placebo groups and 
b OROS-MPH and placebo groups. *p < 0.05; ***p < 0.001; analysis 
of covariance (pre-specified) [10]. †p < 0.05; ††p < 0.01; †††p < 0.001; 
χ2 test (post hoc). All p values are nominal and not adjusted for mul-
tiplicity. Numbers of observations (n) for each group are shown for 
each WFIRS-P domain. WFIRS-P response was defined as a change 
from baseline to endpoint exceeding the published MID [16]. CI con-
fidence interval, LDX lisdexamfetamine dimesylate, MID minimum 
important difference, NS not significant, OROS-MPH osmotic-release 
oral system methylphenidate, WFIRS-P Weiss Functional Impairment 
Rating Scale-Parent Report




Fig. 2  SPD503-316: post hoc responder analysis of change in 
WFIRS-P domain scores in the a GXR and placebo groups and b 
ATX and placebo groups. *p < 0.05; **p < 0.01; analysis of covari-
ance (pre-specified). †p < 0.05; ††p < 0.01; †††p < 0.001; χ2 test (post 
hoc). All p values are nominal and not adjusted for multiplicity, 
except for the pre-specified analysis of the Family domain and the 
Learning and School domain. Numbers of observations (n) for each 
group are shown for each WFIRS-P domain. WFIRS-P response 
was defined as a change from baseline to endpoint exceeding the 
published MID [16]. ATX atomoxetine, CI confidence interval, GXR 
guanfacine extended release, MID minimum important difference, NS 
not significant, WFIRS-P Weiss Functional Impairment Rating Scale-
Parent Report
Table 3  Summary of baseline 
WFIRS-P scores for responders 
and non-responders in studies 
SPD489-325 and SPD503-316
For both studies, baseline differences in WFIRS-P scores between responders and non-responders were 
significant for all domains (all p < 0.001)
SD standard deviation, WFIRS-P Weiss Functional Impairment Rating Scale-Parent Report
WFIRS-P domain SPD489-325 baseline WFIRS-P score, 
mean (SD)
SPD503-316 baseline WFIRS-P 
score, mean (SD)
Responder Non-responder Responder Non-responder
Family 16.1 (6.05) 12.1 (7.75) 18.4 (6.60) 10.2 (6.78)
Learning and School 14.8 (6.27) 10.8 (5.62) 15.6 (5.55) 11.2 (5.85)
Life skills 13.9 (4.47) 9.6 (4.72) 14.4 (4.62) 9.9 (5.02)
Child’s self-concept 4.7 (1.77) 2.5 (2.30) 4.5 (1.84) 2.0 (1.99)
Social activities 9.1 (4.23) 6.3 (4.31) 11.3 (4.65) 5.7 (5.21)
Risky activities 8.0 (3.78) 4.1 (3.35) 7.5 (3.26) 3.4 (2.94)
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participants with ODD and ADHD than in those without 
ODD. SMDs between subgroups were similar for CGI-S 
score and ADHD-RS-IV total score at baseline (0.45 and 
0.50, respectively).
Effect of ADHD presentation
Baseline WFIRS-P scores were significantly worse in par-
ticipants with combined or predominantly hyperactive-
impulsive type ADHD than in those with predominantly 
inattentive type ADHD in all domains except for Child’s 
Self-Concept (Fig. 3d). SMDs between the subgroups were 
largest in the Family and Risky Activities domains (0.65 and 
0.51, respectively). Baseline CGI-S scores and ADHD-RS-
IV total scores were also significantly worse in participants 
with combined or predominantly hyperactive-impulsive type 
ADHD than in those with predominantly inattentive type 
ADHD. The SMD between subgroups was 1.10 for ADHD-
RS-IV total score and 0.59 for CGI-S at baseline.
Discussion
These post hoc analyses revealed that previously reported 
group-level improvements in WFIRS-P functional impair-
ment did in fact translate into clinically relevant improve-
ments in individual participants. Many participants receiving 
ADHD medications in two phase 3 clinical trials experi-
enced meaningful and perceptible improvements in function-
ing, as measured using the WFIRS-P [11, 18]. These results 
support the recommendation that assessment and manage-
ment of ADHD should include evaluation of each patient’s 
functional impairment using a reliable and responsive rating 
scale [15]. To this end, the MID provides a valuable tool for 
interpreting WFIRS-P response.
By stratifying baseline WFIRS-P scores by patient char-
acteristic subgroups in seven phase 3 clinical trials, the pre-
sent analyses also showed that children and adolescents with 
comorbid ODD tend to have worse functional impairment 
than those without comorbid ODD. Having combined type 
or hyperactive-impulsive type ADHD, being enrolled into 
a study in Europe, being male and being younger also had 
modest negative effects on baseline WFIRS-P scores.
In the responder analyses, the WFIRS-P Learning and 
School domain saw the greatest proportions of participants 
with above-MID improvements following treatment with 
LDX or OROS-MPH in study SPD489-325, or with GXR 
or ATX in study SPD503-316. Treatment with LDX, OROS-
MPH and GXR (but not ATX) also led to improvements in 
the Family domain. The stimulants LDX and OROS-MPH 
were associated with improvements in the Risky Activi-
ties domain, whereas the non-stimulants GXR and ATX 
were associated with improvements in the Social Activities 
domain. This apparent difference between stimulants and 
non-stimulants is consistent with previous findings and may 
arise from factors including differing modes of action, as 
well as baseline variations in disease severity and character-
istics in the study populations [15]. Of note, the groups of 
patients who responded in both studies had a greater mean 
impairment at baseline than non-responders. This observa-
tion could result from the greater window for improvement 
in those with highest WFIRS-P scores at baseline. Alter-
natively, regression towards the mean cannot be ruled out.
In an ADHD symptom-based responder analysis of 
SPD489-325, the differences in the proportion of responding 
patients between active medication and placebo were larger 
than those seen for any WFIRS-P domain. In the present 
analyses, the proportion of WFIRS-P responders was larg-
est in the Learning and School domain with 60.0% for LDX 
and 18.4% for placebo. At endpoint in the symptom-based 
responder analysis, the percentages of patients categorized 
as responders were 74.2% for LDX, 55.9% for OROS-MPH 
and 10.7% for placebo. Although in these analyses, symp-
tom response was not based on a MID, but was defined as a 
reduction of at least 30% in ADHD-RS-IV total score from 
baseline and a CGI-I score of 1 or 2 at endpoint [21]. Con-
sistent with the observation that placebo-adjusted response 
rates were generally higher for ADHD-RS-IV/CGI-I based 
criteria than WFIRS-P response rates, mean changes in 
WFIRS-P domain scores correlated moderately with mean 
changes in ADHD symptom-based scores in a previous post 
hoc analysis. An investigation of the associations between 
different symptom-based and non-symptom-based outcomes 
found that the ADHD-RS-IV and the WFIRS-P assess par-
tially intersecting but distinct aspects of the response to 
pharmacological treatment [15]. The nature of functional 
impairment varies from patient to patient, which may 
explain why the observed effect sizes were lower for the 
Table 4  Pearson correlation coefficients for mean baseline WIFRS-P 
and CGI-S scores and mean baseline ADHD-RS-IV total score with 
age
ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale 
IV, CGI-S Clinical Global Impression-Severity, WFIRS-P Weiss 
Functional Impairment Rating Scale-Parent Report
*p < 0.001 (p values > 0.001 not shown)
WFIRS-P domain Pearson’s r
Family − 0.1104*
Learning and School − 0.0501
Life Skills − 0.0458
Child’s Self-Concept + 0.0989*
Social Activities − 0.1483*
Risky Activities − 0.0607
CGI-S − 0.2137*
ADHD-RS-IV − 0.2809*
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WFIRS-P than the ADHD-RS-IV. By definition, all par-
ticipants had poor symptom scores at baseline, but not all 
necessarily had impairment in every WFIRS-P domain. As 
such, the WFIRS-P may help to guide clinical management 




Fig. 3  Baseline WFIRS-P scores stratified by a sex, b continent of 
enrolment, c ODD diagnosis and d ADHD presentation. *p < 0.001 (p 
values > 0.001 not shown). ADHD attention-deficit/hyperactivity dis-
order, ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating 
Scale IV, CGI-S Clinical Global Impression-Severity, CI confidence 
interval, ODD oppositional defiant disorder, SD standard deviation, 
SMD standardized mean difference, WFIRS-P Weiss Functional 
Impairment Rating Scale-Parent Report
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A recent study looked at the relationship between 
symptomatic improvement and functional improvement 
as measured by the WFIRS-P in an open-label study of 
OROS-MPH in children and adolescents with ADHD 
[24]. Significant improvements in all WFIRS-P domains 
were observed from baseline to end of open-label treat-
ment (3 months). However, a substantial number of those 
considered to be symptomatic responders failed to show 
improvement in functioning. Symptomatic response was 
defined as a reduction of at least 30% in ADHD-RS-IV 
total score from baseline, and functional response as a 
mean change from baseline in WFIRS-P score of 0.25 
[24]. These results further highlight the lack of complete 
alignment between symptom improvement and functional 
improvement.
In the present analyses of baseline scores stratified by 
patient characteristic subgroups, differences between sub-
groups in WFIRS-P scores were generally similar in magni-
tude and direction to the differences in clinical symptom and 
severity scores. This relationship varied amongst WFIRS-P 
domains, however, with larger differences in the WFIRS-P 
Family and Risky Activities domains than in CGI-S score 
and ADHD-RS-IV total score differences between partic-
ipants with and without ODD. In contrast, differences in 
the Life Skills, Child’s Self-Concept and Social Activities 
domains were smaller than for CGI-S and ADHD-RS-IV. 
These observed differences between WFIRS-P scores and 
ADHD-RS-IV and CGI-S scores further demonstrate the 
intersecting but distinct aspects of the response to treatment 
captured by the different instruments [15].
Of the factors tested, ODD diagnosis had the largest influ-
ence on pooled baseline WFIRS-P scores and was associated 
with worse scores across all six domains. ADHD-RS-IV and 
CGI-I baseline scores were also worse in participants with 
ODD than in those without ODD, which is consistent with 
ODD and ADHD having some similar and overlapping fea-
tures. The results of the present study likely reflect greater 
severity of both ADHD symptoms and related functional 
impairment amongst participants with ADHD and ODD 
than in those without ODD.
ADHD subtype had a modest influence on functional 
impairment and individuals with combined/hyperactive-
impulsive ADHD scored worse in most domains, particu-
larly in the Family and Risky Activities domains, than those 
with predominantly inattentive ADHD. The effect of ADHD 
subtype was greatest on ADHD-RS-IV baseline score 
(as expected, given that individuals with combined type 
ADHD have a potentially broader range of symptoms than 
those with inattentive or hyperactive-impulsive type). The 
effects of age and sex on baseline WFIRS-P, ADHD-RS-IV 
and CGI-S scores were small. Respondents may not have 
scored impairments equally in patients of different ages. The 
requirement for CGI-S scores of four or more in many of the 
trials included in the pooled data set may have led to exclu-
sion of girls with very mild functional impairment.
The worse baseline WFIRS-P scores observed in Europe 
than in North America could be caused by the pooling of 
several studies with different enrolment criteria; for exam-
ple, the minimum baseline ADHD-RS-IV total score varied 
between 28 and 32, but could also reflect a higher thresh-
old for diagnosis in Europe than in North America. A tel-
ephone survey conducted in the USA in 2011 revealed that 
11% of US school-aged children had received a diagnosis 
of ADHD [25], whereas the pooled worldwide prevalence 
is estimated to be 5.29% [26]. However, a meta-regression 
analysis showed that the prevalence estimates for ADHD in 
Europe and North America were not significantly different 
[27]. Given the potential differences observed in the present 
study, it is perhaps a topic worthy of further investigation.
A key strength of the responder analyses was the use of 
published MID values to define WFIRS-P response. Infor-
mation about individual response is important to clinicians, 
in addition to what is known about group-level responses 
to treatment. Analysis of raw scores may not be the best 
way to tell if an individual has improved. To this end, MIDs 
provide an important way to interpret patient-reported out-
comes, which are often the outcomes of most importance 
to patients and their families [28]. A further strength is the 
use of MIDs derived from an anchor method, which indicate 
the perceived importance of a change, rather than distribu-
tional methods that are based solely on variation around the 
group mean [16]. These MIDs were based on estimates cal-
culated in a naturalistic community sample with no interven-
tion, thereby reducing potential bias [16]. Further strengths 
include the size of the datasets analysed, with the responder 
analyses including over 300 participants in each trial and the 
pooled baseline impairment analyses including over 2000 
participants. In the responder analyses, the proportions of 
stimulant-naïve participants were similar across all treat-
ment groups, suggesting that previous drug status is unlikely 
to affect the treatment groups differentially. Furthermore, 
response to LDX and GXR has been shown to be unaffected 
by prior stimulant treatment [18, 22].
The use of clinical trial populations was a key limitation 
of the present analysis. Pooling data from seven studies with 
different inclusion and exclusion criteria to increase statis-
tical power may have confounded the analyses of baseline 
characteristics in subgroups. Notably, the response rates of 
active and placebo arms in SPD503-316 were higher than 
the response rates in SPD489-325, which is an argument 
against pooling outcome data. Another limitation of the 
present analyses is that clinical trial populations may not be 
representative of patients seen in general clinical practice. 
Further limitations include the short-term nature of the stud-
ies, which preclude evaluation of the long-term impact of 
ADHD treatments on functional outcomes. Improvements in 
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functional impairment may develop over a longer period of 
treatment than relief of ADHD symptoms. Although using 
the parent-rated WFIRS-P overcomes possible unreliable 
self-rating by young people with ADHD, it also introduces 
the potential for misinterpretation of the affected individual’s 
true response. In addition, the studies described here were 
powered for the primary outcome of assessing efficacy using 
ADHD-RS-IV, whereas assessment of the WFIRS-P was a 
secondary outcome. Furthermore, studies SPD489-325 and 
SPD503-316 were not designed or powered for direct com-
parison of the test drugs (LDX and GXR, respectively) with 
the active controls (OROS-MPH and ATX, respectively). 
Finally, both the responder and baseline impairment analy-
ses are limited by the risk of bias associated with post hoc 
analyses.
The effect of ADHD medications in different subgroups 
could not be assessed in the present analyses because the 
numbers of participants in subgroups within each study were 
too small for reliable comparisons. Previous subgroup analy-
ses have assessed the efficacy of GXR, LDX and OROS-
MPH in participants with and without previous exposure 
to stimulant ADHD medication [18, 22], as well as the effi-
cacy of GXR in individuals with ADHD and oppositional 
symptoms [29]. Future studies could perhaps explore the 
effect of ADHD medications in different subgroups such as 
those described here. In addition, it would be interesting to 
explore the temporal profile of medication activity. Previous 
studies have shown GXR to result in consistent symptomatic 
responses, regardless of the time of administration [12, 29, 
30]. Different formulations of psychostimulants, however, 
may differentially affect certain WFIRS-P domains depend-
ing on their duration of action. For example, if systemic con-
centrations of a medication have declined, then the potential 
benefits in the Family and Social Activities domains may be 
lost. Assessment of response in individuals receiving com-
bination therapy would also provide insight into benefits 
provided by different mechanisms of action.
Conclusion
In conclusion, the large placebo-adjusted effect sizes of 
ADHD medications in two short-term clinical studies did 
translate into clinically relevant improvements in WFIRS-P 
functional impairment scores for many patients receiving 
pharmacotherapy with LDX, OROS-MPH, GXR and ATX in 
the present responder analyses. Longer-term studies may be 
needed to reveal the treatment effects of ADHD medication 
on functional impairment beyond what has been shown here. 
Functional impairment is a diverse and subjective construct 
that is influenced by multiple factors including comorbidity, 
age, sex and geography. Not only relief of ADHD symp-
toms, but also a reduction of patients’ related but distinct 
functional impairments, is achievable with medication in 
many children and adolescents with ADHD. As such, opti-
mal management should involve monitoring improvement 
in functioning and quality of life, as well as symptomatic 
improvement.
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